Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in...

Full description

Bibliographic Details
Main Authors: Valérie Dutoit, Denis Migliorini, Giulia Ranzanici, Eliana Marinari, Valérie Widmer, Johannes Alexander Lobrinus, Shahan Momjian, Joseph Costello, Paul R. Walker, Hideho Okada, Toni Weinschenk, Christel Herold-Mende, Pierre-Yves Dietrich
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
grade ii glioma
grade iii glioma
immunotherapy
peptide vaccine
ima950
spontaneous t cell responses
astrocytoma
oligodendroglioma
ependymoma
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1391972

Internet

http://dx.doi.org/10.1080/2162402X.2017.1391972

Similar Items